Skip to main content
. 2021 Jun 12;13(12):2950. doi: 10.3390/cancers13122950

Figure 7.

Figure 7

Comparison of V and J-gene usage between anti-PD-1 treated NSCLC patients with DCB vs. non-DCB. (a) V-gene usage in pretreatment (PRE) and first response assessment (FR) samples. (b) J-gene usage in PRE samples. Statistical analysis was performed using the Mann–Whitney test. The height of each column represents the median of the frequency and the error bars depict the interquartile range. DCB: durable clinical benefit, in green; non-DCB: non-durable clinical benefit, in orange. * p < 0.05.